These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38072987)

  • 1. Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report.
    Takakura A; Hirai T; Hamaguchi N; Mukohara R; Matsumoto K; Yano Y; Iwamoto T
    J Pharm Health Care Sci; 2023 Dec; 9(1):46. PubMed ID: 38072987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
    Jung JA; Kaku K; Kim JH; Kim JR; Ko JW; Lee SY; Huh W
    Adv Ther; 2013 Nov; 30(11):1018-29. PubMed ID: 24249434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
    Ando K; Nishimura R; Seo C; Tsujino D; Sakamoto M; Utsunomiya K
    Expert Opin Pharmacother; 2014 Dec; 15(17):2479-85. PubMed ID: 25327311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
    Baek JH; Jin SM; Kaku K; Jung JA; Kim JR; Ko JW; Kim MJ; Lee SY; Huh WS; Kim JH
    Expert Opin Pharmacother; 2015 Jun; 16(8):1127-36. PubMed ID: 25881690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
    Ono Y; Kamoshima H; Nakamura A; Nomoto H
    Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes.
    Arao T; Okada Y; Torimoto K; Sugai K; Otsuka T; Kurozumi A; Tanaka Y
    J UOEH; 2017; 39(1):1-9. PubMed ID: 28331117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case control study.
    Sakurama K; Iguchi Y; Haruki S; Hata Y; Hiraga M; Yumoto S; Kai Y
    J Pharm Health Care Sci; 2023 Apr; 9(1):13. PubMed ID: 37032382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes.
    Akahane K; Ojima K; Yokoyama A; Inoue T; Kiguchi S; Tatemichi S; Takeda H; Kobayashi M
    Drug Res (Stuttg); 2017 Jul; 67(7):396-403. PubMed ID: 28486736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
    Osonoi T; Saito M; Tamasawa A; Ishida H; Osonoi Y
    Expert Opin Pharmacother; 2014 Jul; 15(10):1325-35. PubMed ID: 24866329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study.
    Takeshita Y; Takamura T; Kita Y; Takazakura A; Kato K; Isobe Y; Kaneko S
    BMJ Open Diabetes Res Care; 2015; 3(1):e000122. PubMed ID: 26336611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
    Seo C; Sakamoto M; Nishimura R; Tsujino D; Ando K; Morimoto A; Utsunomiya K
    Diabetes Technol Ther; 2013 May; 15(5):378-85. PubMed ID: 23634671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
    Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin.
    Murakami T; Nambu T; Kato T; Matsuda Y; Yonemitsu S; Muro S; Oki S
    Tohoku J Exp Med; 2015 Apr; 235(4):255-60. PubMed ID: 25810423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
    Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
    J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study.
    Akagi Y; Iketaki A; Kimura H; Matsudaira Y; Yoshida T; Nishimura T; Kawano Y; Mano Y; Shigematsu E; Ujihara M
    J Pharm Health Care Sci; 2020; 6():5. PubMed ID: 32206324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.
    Ono Y; Nakamura A; Cho KY; Nomoto H
    Expert Opin Pharmacother; 2014 Feb; 15(3):311-24. PubMed ID: 24328511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
    Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.